My brain dump below. Formatting is a bit ugly apologies.
I think it's a really clever partnership and will accelerate our pathway.
i tried to ask twice about financing because ideas are great but how is adalta going to pay for it?
sounds like synthesis has money but we don't.
otherwise, great presentation. Let me know if anything below doesn't make sense.
• Andrew Walks - synthesis
• Venture capital - invest in good biotechs
• China experience
• Still focussed on AD214
• Very pleased so far with negotiations
• This announcement for number 3 workstream
• Allows progression without waiting for AD214
• CarT benefits financial
• Upfront median $25m and deal value 730
• Transact pre-clinical
• Best way for adalta to play in this space?
• East to west strategy
• ASIA -
○ most developers of drugs - mostly China
○ Equal to America in size
○ Lots of clinical trials
• Aust
○ 25%-50% cheaper than US in CAR T
○ Great manufacturing
• China needs Aust - geopolitical issues
• Still early days
• How will adalta put money in?
• Pipeline of 10 assets - 6 on the board
• Needs to be manufactured near the subjects?
• China IP to western markets
• Cellular immunotherapy
• Using own cells to treat disease - Tcells specific to targets, innate immune system
• Can modify them - found in tumours, use to infiltrate other tumours
• CAR T - engineer receptors to go find cancers - using T cells
• Timeline
• Active pipeline been accumulating over 12 months - initial collab - 6 month period of time then extend 6 months
• Revenue
• Business model - adcella - develop assets, de-risk then on-licence to larger companies for commercialisation
• Value add - first western data and GMP manufacturing -
Timeline - 6-9 month window for tech transfer, 12-24 months for phase 1 trial then transactable asset - 3 year to acquire and licence
(20min delay)